Vnitr Lek 2005, 51(5):504-509

Our experience in the treatment of membranous nephropathy with cyclosporine

M. Janeček*, Z. Říhová, V. Tesař, M. Merta, D. Kmentová
Klinika nefrologie 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Vladimír Tesař, DrSc.

In a group of 17 patients with primary membranous glomerulonephritis, we assessed the impact of cyclosporine therapy on proteinuria and glomerular filtration. The indications for treatment with cyclosporine were: nephrotic syndrome resistant to chlorambucil (10 patients), cyclophosphamide (2 patients) or cyclophosphamide and chlorambucil (1 patient). We also treated with cyclosporine 3 patients with a high risk of thromboembolic complications (proteinuria above 10 g/24 hours) and one young patient was treated with cyclosporine at a dose not exceeding the gonadotoxic dose of cyclophosphamide. Treatment was started at a dose of 5 mg/kg/day and adjustments in dosages were made to achieve a trough plasma level of cyclosporine between 80-120 ng/ml, as measured by High Performance Liquid Chromatography. Simultaneously, we administered corticosteroids in a daily dose of 20 mg of prednisone or less. We followed the levels of proteinuria, serum creatinine and creatinine clearance before the treatment with cyclosporine, after one year of treatment, and at one and two years after withdrawal of cyclosporine. After one year of therapy, we observed a decline in proteinuria from 10.5 (3.1-35) to 1.7 (0.22-17.4) g/24 hours [median (range)]. This was a statistically significant decline remaining one and two years after stopping cyclosporine (Wilcoxon's paired test p < 0.01). The decline in proteinuria, after either one year of treatment and at one year after stopping treatment, was also significant in the subset of patients with membranous nephropathy refractory to chlorambucil. Our evaluation of changes in glomerular filtration using the reciprocal value of serum creatinine revealed a possible transient decline in renal function after one year of cyclosporine therapy, but we did not observe a corresponding change in creatinine clearance. Our experience confirms the importance of cyclosporine in the treatment of membranous nephropathy and shows the effectiveness of this drug even in cases refractory to prior treatment with chlorambucil.

Keywords: cyclosporine; membranous nephropathy; glomerulonephritis

Received: May 13, 2003; Accepted: August 23, 2004; Published: May 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janeček M, Říhová Z, Tesař V, Merta M, Kmentová D. Our experience in the treatment of membranous nephropathy with cyclosporine. Vnitr Lek. 2005;51(5):504-509.
Download citation

References

  1. Cattran DC, Appel GB, Hebert LA et al. Cyklosporin in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 2001; 59: 1484-1490. Go to original source... Go to PubMed...
  2. Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 1995; 47: 1130-1135. Go to original source... Go to PubMed...
  3. Cattran DC, Pei Y, Greenwood CMT et al. Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 1997; 51: 901-907. Go to original source... Go to PubMed...
  4. Fritsche L, Budde K, Färber L et al. Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? Nephrol Dial Transplant 1999; 14: 1036-1038. Go to original source... Go to PubMed...
  5. Muirhead N. Management of idiopathic membranous nephropathy. Evidence-based recommendations. Kidney Int 1999; 70(Suppl): S47-S55. Go to original source... Go to PubMed...
  6. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1997; 51: 901-907. Go to original source... Go to PubMed...
  7. Polenakovic MH, Grcevska L. Treatment and Long Term Follow-Up of Patients With Stage II to III Idiopathic Membranous Nephropathy. Am J Kidney Dis 1999; 34: 911-917. Go to original source... Go to PubMed...
  8. Ponticelli C, Zucchelli P, Passerini P et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med 1992; 327: 599-603. Go to original source... Go to PubMed...
  9. Rostoker G, Belghiti D, Maadi A et al. Long-Term Cyclosporin A Therapy for Severe Idiopathic Membranous Nephropathy. Nephron 1993; 63: 335-341. Go to original source... Go to PubMed...
  10. Schück O, Tesař V, Teplan V et al. Klinická nefrologie. Praha: Medprint 1995.
  11. Teplan V. Měření glomerulární filtrace - komentář. Medicína po promoci 2002; 3: 46-49.
  12. Zvárová J. Základy statistiky pro biomedicínské obory. Praha: Karolinum 1998.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.